Bio-Techne stock rallies 6.49% and outperforms competitors

11 articles · Updated · MarketWatch · Apr 30

The shares closed at $55.32 on Thursday as the S&P 500 rose 1.02% to 7,209.01 and the Dow gained 1.62% to 49,652.14.
The advance ended a two-day losing streak and beat peers including Amgen and Charles River Laboratories, while BioMarin Pharmaceutical slipped 0.55%.
Trading volume reached 3.5 million shares, above the 50-day average of 2.2 million, though the stock remains 23.34% below its 52-week high of $72.16.

With a sky-high P/E ratio but 'undervalued' analyst ratings, what is the true financial health of Bio-Techne?

Amid a biotech M&A boom, is Bio-Techne's internal restructuring a path to independent growth or a prelude to acquisition?